{"id":794742,"date":"2024-12-12T18:37:13","date_gmt":"2024-12-12T23:37:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/"},"modified":"2024-12-12T18:37:13","modified_gmt":"2024-12-12T23:37:13","slug":"investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/","title":{"rendered":"INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (Nasdaq: KYTX); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, Dec.  12, 2024  (GLOBE NEWSWIRE) &#8212; A class action lawsuit has been filed on behalf of all persons and entities who purchased or otherwise acquired Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (\u201cKyverna\u201d or the \u201cCompany\u201d) common stock pursuant and\/or traceable to the Company\u2019s registration statement issued in connection with its initial public offering (\u201cIPO\u201d) held on February 8, 2024. The Kyverna lawsuit charges the Company, certain of its current and former senior executives and directors, and the underwriters of Kyverna\u2019s IPO with violations of the federal securities laws (collectively, \u201cDefendants\u201d).<\/p>\n<p align=\"justify\">Kyverna investors have until February 7, 2025 to seek appointment as lead plaintiff of the Kyverna class action lawsuit.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>If you purchased or acquired Kyverna common stock pursuant and\/or traceable to the Company\u2019s registration statement issued in connection with its IPO on February 8, 2024, and suffered substantial losses<\/em><br \/>\n        <\/strong>, and you wish to obtain additional information or serve as lead plaintiff in this lawsuit, you may <strong><em>submit your information and contact us here: <\/em><\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rYLfio4s35Gh5-atvqise4vnAuVpEpREHtrQovUc5BXCX5bnNcah_uaVaYJJZ29DI9m80qxzwtSqh_F0Xew17glKKuVCowOxEAWEXtxofkqPWueIZnzj7u7q1fN80nZyTFXltf7m2TJc6dmEZ2rjefL0Ihiwfe3EGmlCg0lcwSk=\" rel=\"nofollow\" target=\"_blank\">https:\/\/dicellolevitt.com\/securities\/kyverna\/<\/a>.<\/p>\n<p align=\"justify\">You can also contact DiCello Levitt attorneys Brian O\u2019Mara or Ruben Pe\u00f1a by calling (888) 287-9005 or emailing <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pYj9K_KTQQ_nQ2JIepFEmOLQOtE3-HmZBTMAKKl4Q63Vx3r_H-PP81ohEGh_eAbWhWIEk7cq2WgnRGQ60Ze_9LptAyeCMII32yBmeeAJYfJQdUwU2YJIT44snJw2mZpP\" rel=\"nofollow\" target=\"_blank\">investors@dicellolevitt.com<\/a>. Those who inquire by email are encouraged to include their mailing address, telephone number, and the number of shares purchased.<\/p>\n<p align=\"justify\">No Class Has Been Certified.\u00a0\u00a0 Until a class is certified, you are not represented by counsel unless you retain one.\u00a0\u00a0 You may select counsel of your choice.<\/p>\n<p>\n        <strong>Case Allegations<\/strong>\n      <\/p>\n<p align=\"justify\">Kyverna is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. During its IPO, Kyverna offered 14.5 million shares of common stock at $22.00 per share, resulting in the Company receiving approximately $296 million in net proceeds.<\/p>\n<p align=\"justify\">The Kyverna lawsuit alleges that the IPO\u2019s registration statement contained false and misleading statements and\/or concealed material adverse facts, including that: (i) Kyverna did not disclose negative information about one of its clinical trials; (ii) the undisclosed negative information was likely to, and eventually did, substantially and negatively affect Kyverna\u2019s main product, making the information and trends disclosed in the registration statement, false, misleading, and not indicative of Kyverna\u2019s business prospects; (iii) Kyverna\u2019s statements about risk factors did not to adequately disclose the risk posed by Kyverna\u2019s nondisclosure of adverse information about one of its clinical trials, that other adverse results and trends had already manifested or the probable materially negative effects on Kyverna\u2019s future results, share price, and prospects.<\/p>\n<p align=\"justify\">The truth began to emerge on June 14, 2024, when Kyverna published an investor presentation that revealed adverse data about one of its clinical trials. The Kyverna lawsuit alleges the Company\u2019s shares plummeted after this data was disclosed.<\/p>\n<p align=\"justify\">In fact, by the filing of the Kyverna lawsuit, the Company\u2019s stock had traded as low as $3.92 per share, a decline of more than 82% from the IPO\u2019s price per share.<\/p>\n<p align=\"justify\">\n        <strong>About DiCello Levitt<\/strong>\n      <\/p>\n<p align=\"justify\">At DiCello Levitt, we are dedicated to achieving justice for our clients through class action, business-to-business, public client, whistleblower, personal injury, civil and human rights, and mass tort litigation. Our lawyers are highly respected for their ability to litigate and win cases \u2013 whether by trial, settlement, or otherwise \u2013 for people who have suffered harm, global corporations that have sustained significant economic losses, and public clients seeking to protect their citizens\u2019 rights and interests. Every day, we put our reputations \u2013 and our capital \u2013 on the line for our clients.<\/p>\n<p align=\"justify\">DiCello Levitt has achieved top recognition as Plaintiffs Firm of the Year and Trial Innovation Firm of the Year by the <em>National Law Journal<\/em>, in addition to its top-tier <em>Chambers<\/em> and <em>Benchmark<\/em> ratings. The <em>New York Law Journal<\/em> also recently recognized DiCello Levitt as a Distinguished Leader in trial innovation. For more information about the Firm, including recent trial victories and case resolutions, please visit www.dicellolevitt.com.<\/p>\n<p align=\"justify\">Attorney Advertising. Prior results do not guarantee a similar outcome.<\/p>\n<p>\n        <strong>Media Contact<\/strong>\n      <\/p>\n<p align=\"justify\">Amy Coker<br \/>4747 Executive Drive, Suite 240<br \/>San Diego, CA 92121<br \/>619-963-2426<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pYj9K_KTQQ_nQ2JIepFEmOLQOtE3-HmZBTMAKKl4Q63PUjJFVta-sgQJrQhMQlukd1WFBuJOPua4fRlEamXYKT_U2Zo-fxPHAhQoG0qHEt4djBE5h5Wkf8mVUFPR8psf\" rel=\"nofollow\" target=\"_blank\">investors@dicellolevitt.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODc3OCM2NjM2MDY0IzIyNzUwODI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjA2ZGJhNmMtOTg4MC00MTljLTg1MDAtNzJjMWU1ZDE4MjA1LTEyODY2MzI=\/tiny\/DiCello-Levitt-LLP.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) &#8212; A class action lawsuit has been filed on behalf of all persons and entities who purchased or otherwise acquired Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (\u201cKyverna\u201d or the \u201cCompany\u201d) common stock pursuant and\/or traceable to the Company\u2019s registration statement issued in connection with its initial public offering (\u201cIPO\u201d) held on February 8, 2024. The Kyverna lawsuit charges the Company, certain of its current and former senior executives and directors, and the underwriters of Kyverna\u2019s IPO with violations of the federal securities laws (collectively, \u201cDefendants\u201d). Kyverna investors have until February 7, 2025 to seek appointment as lead plaintiff of the Kyverna class action lawsuit. If you purchased or acquired Kyverna common stock pursuant and\/or &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (Nasdaq: KYTX); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-794742","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (Nasdaq: KYTX); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (Nasdaq: KYTX); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) &#8212; A class action lawsuit has been filed on behalf of all persons and entities who purchased or otherwise acquired Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (\u201cKyverna\u201d or the \u201cCompany\u201d) common stock pursuant and\/or traceable to the Company\u2019s registration statement issued in connection with its initial public offering (\u201cIPO\u201d) held on February 8, 2024. The Kyverna lawsuit charges the Company, certain of its current and former senior executives and directors, and the underwriters of Kyverna\u2019s IPO with violations of the federal securities laws (collectively, \u201cDefendants\u201d). Kyverna investors have until February 7, 2025 to seek appointment as lead plaintiff of the Kyverna class action lawsuit. If you purchased or acquired Kyverna common stock pursuant and\/or &hellip; Continue reading &quot;INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (Nasdaq: KYTX); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-12T23:37:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODc3OCM2NjM2MDY0IzIyNzUwODI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (Nasdaq: KYTX); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel\",\"datePublished\":\"2024-12-12T23:37:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\\\/\"},\"wordCount\":683,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxODc3OCM2NjM2MDY0IzIyNzUwODI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\\\/\",\"name\":\"INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (Nasdaq: KYTX); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxODc3OCM2NjM2MDY0IzIyNzUwODI=\",\"datePublished\":\"2024-12-12T23:37:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxODc3OCM2NjM2MDY0IzIyNzUwODI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxODc3OCM2NjM2MDY0IzIyNzUwODI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (Nasdaq: KYTX); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (Nasdaq: KYTX); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/","og_locale":"en_US","og_type":"article","og_title":"INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (Nasdaq: KYTX); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel - Market Newsdesk","og_description":"SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) &#8212; A class action lawsuit has been filed on behalf of all persons and entities who purchased or otherwise acquired Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (\u201cKyverna\u201d or the \u201cCompany\u201d) common stock pursuant and\/or traceable to the Company\u2019s registration statement issued in connection with its initial public offering (\u201cIPO\u201d) held on February 8, 2024. The Kyverna lawsuit charges the Company, certain of its current and former senior executives and directors, and the underwriters of Kyverna\u2019s IPO with violations of the federal securities laws (collectively, \u201cDefendants\u201d). Kyverna investors have until February 7, 2025 to seek appointment as lead plaintiff of the Kyverna class action lawsuit. If you purchased or acquired Kyverna common stock pursuant and\/or &hellip; Continue reading \"INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (Nasdaq: KYTX); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-12T23:37:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODc3OCM2NjM2MDY0IzIyNzUwODI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (Nasdaq: KYTX); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel","datePublished":"2024-12-12T23:37:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/"},"wordCount":683,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODc3OCM2NjM2MDY0IzIyNzUwODI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/","name":"INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (Nasdaq: KYTX); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODc3OCM2NjM2MDY0IzIyNzUwODI=","datePublished":"2024-12-12T23:37:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODc3OCM2NjM2MDY0IzIyNzUwODI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODc3OCM2NjM2MDY0IzIyNzUwODI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-shareholder-class-action-lawsuit-filed-against-kyverna-therapeutics-inc-nasdaq-kytx-dicello-levitt-llp-encourages-investors-with-losses-to-discuss-their-options-with-counsel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (Nasdaq: KYTX); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/794742","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=794742"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/794742\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=794742"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=794742"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=794742"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}